文献速递临床试验与 GCP真实世界研究与卫生经济

节律性听觉刺激治疗卒中的结局与卫生经济学(OrcHESTRAS):MR-001用于慢性卒中的实用性、去中心化、纵向、多阶段、撤除后随机再治疗试验方案

Outcomes and Health Economics of Stroke using Rhythmic Auditory Stimulation (OrcHESTRAS): a protocol for a pragmatic, decentralized, longitudinal, multi-phase, withdrawal with randomized re-treatment trial of MR-001 in chronic stroke.
PubMed 文献 · Trials · 2026-01-08

本研究为去中心化纵向试验,纳入约225例慢性卒中伴步态障碍患者,先接受12周MR-001治疗(每次30分钟、每周3次)后洗脱12周,再随机接受12周MR-001或24周延长洗脱,主要终点为第一步中达到至少中度参与的比例,并评估步行耐力、生活质量及医疗资源利用等。

要点

  • MR-001为自主神经康复系统,提供个性化节律性听觉刺激用于居家步行康复。
  • 试验采用实用性单臂干预期与随机再治疗期相结合的混合设计。
  • 探索性分析包括再治疗效果、应答者预测因素及基于理赔数据的医疗资源利用。

核心结论

  • 该实用性试验评估MR-001的参与度、疗效持久性及再治疗效果,并关联理赔数据以生成居家节律性听觉刺激经济影响的初步证据。
  • 研究结果将用于指导优化依从性、支持支付方报销及将MR-001整合入长期卒中照护的策略。

研究设计与样本

  • 去中心化、纵向、多阶段、撤除后随机再治疗试验,结合实用性单臂干预期与随机再治疗期。
  • 计划纳入约225例慢性卒中伴步态障碍参与者。
  • 第一步:所有参与者接受12周MR-001治疗(每次30分钟、每周3次),随后12周洗脱。
  • 第二步:参与者随机接受额外12周MR-001治疗或24周延长洗脱。

关键数值与推荐

  • 主要终点为用户参与度,定义为第一步期间达到至少中度参与的比例。
  • 次要终点包括步行耐力、获益持久性、生活质量、日常生活活动、社交隔离及认知功能。
  • 探索性分析包括一般移动能力变化、再治疗效果、按基线功能与参与度的亚组分析、应答者比例与预测因素,以及通过理赔数据评估的医疗资源利用。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Persistent gait deficits limiting mobility, independence, and quality of life are common after stroke. These deficits also increase fall risk, hospitalizations, and mortality, driving substantial clinical and economic burden. Interventions that improve gait may reduce these risks and associated costs. Rhythmic auditory stimulation (RAS) is a validated technique that enhances gait parameters, including speed, cadence, and stride symmetry in stroke rehabilitation. MR-001 is an autonomous neurorehabilitation system that delivers personalized RAS for home-based walking rehabilitation. This study incorporates pragmatic and controlled design elements, consistent with real-world implementation settings, to evaluate engagement, clinical effectiveness, durability of response, and health economic impact of MR-001 in people living with gait impairment after stroke. METHODS: This decentralized, longitudinal trial combines a pragmatic single-arm intervention phase with a randomized re-treatment phase. Approximately 225 participants with chronic stroke and gait deficit will be enrolled. In Step 1, all participants receive 12 weeks of MR-001 therapy (30 min, 3 times per week) followed by a 12-week washout. In Step 2, participants are randomized to either 12 additional weeks of MR-001 or a 24-week extended washout. The primary endpoint is user engagement, defined as the proportion achieving at least moderate engagement during Step 1. Secondary endpoints include walking endurance, durability of gains, quality of life, activities of daily living, social isolation, and cognitive function. Exploratory analyses include changes to general mobility, effects of re-treatment, subgroup analyses by baseline function and engagement, proportion and predictors of responders, and healthcare resource utilization assessed through claims data. DISCUSSION: This pragmatic trial evaluates MR-001, a technology-enabled, autonomous neurorehabilitation system. The design expands on earlier work to assess engagement, durability, and re-treatment while linking clinical outcomes to claims data to generate preliminary evidence on the economic impact of home-based RAS. Findings will inform strategies to optimize adherence, support payer reimbursement, and guide the integration of MR-001 into long-term stroke care. TRIAL REGISTRATION: ClinicalTrials.gov NCT06051539. Registered on 20 September 2023 https://clinicaltrials.gov/study/NCT06051539 .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Taylor SR, Awad LN, Carlowicz CA, et al. Outcomes and Health Economics of Stroke using Rhythmic Auditory Stimulation (OrcHESTRAS): a protocol for a pragmatic, decentralized, longitudinal, multi-phase, withdrawal with randomized re-treatment trial of MR-001 in chronic stroke. Trials. 2026. PMID: 41501870. doi:10.1186/s13063-025-09415-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。